ANTH Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Anthera Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0002 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -99.00% |
| 1 Year Change | 0% |
| 3 Year Change | 0% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| ANTH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 3.2% |
| 1Y | 0% | -7.0% | 24.2% |
Return vs Industry: ANTH exceeded the US Biotechs industry which returned -7% over the past year.
Return vs Market: ANTH underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| ANTH volatility | |
|---|---|
| ANTH Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ANTH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ANTH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | John Thompson | www.anthera.com |
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company.
Anthera Pharmaceuticals, Inc. Fundamentals Summary
| ANTH fundamental statistics | |
|---|---|
| Market cap | US$26.00 |
| Earnings (TTM) | -US$24.93m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ANTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANTH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$28.26m |
| Gross Profit | -US$28.26m |
| Other Expenses | -US$3.33m |
| Earnings | -US$24.93m |
Last Reported Earnings
Mar 31, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ANTH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 13:31 |
| End of Day Share Price | 2025/01/13 00:00 |
| Earnings | 2018/03/31 |
| Annual Earnings | 2017/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Anthera Pharmaceuticals, Inc. is covered by 14 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Ascendiant Capital Markets LLC |
| Ritu Baral | Canaccord Genuity |
| Salveen Richter | Collins Stewart LLC |